Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

Singal, Ashwani K.; Freeman, Daniel; Anand, B S

doi:10.1111/j.1365-2036.2010.04414.x

Cited by 112 publications

(89 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subgroup analysis of both the median tumor size less than 3 cm and more than 3 cm groups showed the same result in survival. The result is in accord with other meta-analyses before [29,30,36,37]. We reasoned this phenomenon as follows: firstly, IFN can relieve active-hepatitis and improving hepatic fibrosis and liver function; to be next, decrease the severity of a recurrent tumor and thus be amenable to secondary curative ablation or resection.…”

Section: Discussionsupporting

confidence: 72%

Effect of Adjuvant Interferon Therapy on Hepatitis B/C Virus-Related Hepatocellular Carcinoma After Curative Therapy - Meta-Analysis

Xu¹,

Li²,

Chen³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma is the fifth most common malignant cancer in the world. Liver resection and local ablation are the most effective therapeutic approaches for most HCC patients. Recurrence after curative therapy is very common. Some studies reveal that IFNs have an effect on recurrence. While the opinion is disagreement. Objectives. The aim of this meta-analysis was to evaluate whether interferon therapy could reduce the recurrence of patients of hepatitis B/C virus-related hepatocellular carcinoma after curative therapy. Material and Methods. All randomized controlled trials about interferon on recurrence of hepatitis B/C virus--related hepatocellular carcinoma patients after curative surgery treatment were searched from PubMed, Embase, Cochrane library (all from 1977 to January 2014). Two reviewers independently assessed the quality of each included study and extracted data. RevMan 5.1 was used for meta-analysis. Results. Pooled data analysis revealed that the interferon group had no statistical significance on the recurrence of hepatitis-related hepatocellular carcinoma compared to the control group (RR = 0.91, 95% CI, 0.82 to 1.00); p = 0.11). While from the subgroup analysis of adjuvant interferon can reduce the recurrence of the median tumor size below 3 cm (RR 0.50, p = 0.00002). Conclusions. Adjuvant IFN after curative treatment of hepatitis-related HCC can improve the survival of HCC patients. In addition, IFN could decrease the recurrence rate of HCC patient with median tumor size below 3 cm but not exceeding 3 cm (Adv Clin Exp Med 2015, 24, 2, 331-340).

show abstract

Section: Discussionsupporting

confidence: 72%

Effect of Adjuvant Interferon Therapy on Hepatitis B/C Virus-Related Hepatocellular Carcinoma After Curative Therapy - Meta-Analysis

Xu¹,

Li²,

Chen³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…30 Several studies have reported the survival benefits of IFN therapy following HCC treatment. 12,[31][32][33] Five-year survival rates of IFN groups were 68-91%. 31,33 In this study, the 5-year survival rate of C-HCC patients treated with IFN-based therapy Figure 1 Overall survival in hepatitis B-related hepatocellular carcinoma patients according to the cohort.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that nucleoside/nucleotide analogs (NA) in hepatitis Brelated HCC (B-HCC) and interferon (IFN)-based therapy in hepatitis C-related HCC (C-HCC) had beneficial effects in terms of preventing recurrence and preserving liver function. [12][13][14] However, these trials enrolled only selected patients with specific conditions. It is not well documented whether the prognosis outside of clinical trials actually improved following radical percutaneous therapy.…”

Section: Introductionmentioning

confidence: 99%

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Minami

Tateishi

Shiina

et al. 2015

Hepatology Research

View full text Add to dashboard Cite

Aim: Treatment strategies for hepatocellular carcinoma (HCC) have been advanced. The aim of this study was to compare the change of the prognosis between hepatitis B-related HCC (B-HCC) and hepatitis C-related HCC (C-HCC) in the last two decades. Results: Two (11%), 24 (49%) and 80 (82%) B-HCC patients received nucleoside/nucleotide analogs during the follow-up period in cohorts 1-3, respectively. Among them 1, 18 and 62 patients achieved viral remission, respectively. Thirty-four (18%), 35 (8%) and 84 (14%) C-HCC patients received interferon therapy, respectively. The 5-year B-HCC (P < 0.001) survival rates were 52.6%, 61.1% and 81.6% for cohorts 1-3, respectively. However, the survival rates were 55.6%, 58.8% and 61.1% for C-HCC (P = 0.12), respectively. The B-HCC prognosis improved dramatically (P < 0.001) over time, whereas the prognosis of C-HCC improved moderately (P = 0.01). Methods: Conclusion:The prognosis of B-HCC has improved dramatically over time, whereas that of C-HCC has improved moderately.

show abstract

“…Interferon has a variety of biologic properties, including antiviral, immunomodulatory, antiproliferative, antiangiogenic, and tumouricidal effects. It is reported that interferon is effective in preventing the development of HCC recurrence after its curative treatment in HCV-related cirrhosis [23]. However, interferon treatment also has side-effects, including flu-like symptoms, fatigue, neutropenia, thrombocytopenia, depression, bone marrow suppression, and unmasking or exacerbation of autoimmune illnesses, which lead either to treatment disruption or dose modification.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant Intrahepatic Injection Iodine-131-Lipiodol Improves Prognosis of Patients with Hepatocellular Carcinoma After Resection: a Meta-Analysis

Feng

et al. 2015

Indian J Surg

View full text Add to dashboard Cite

High incidence of intrahepatic recurrence is a major surgical limitation following hepatectomy of hepatocellular carcinoma (HCC). This study was intended to investigate the effects of adjuvant intrahepatic injection of iodine-131-lipiodol on disease recurrence and survival in patients with HCC who underwent resection. A computerized literature search was performed to identify relevant articles. Data synthesis was performed using Review Manager 5.0 software, and results are presented as odds ratio (OR) with 95 % confidence intervals. Two randomized controlled trials and three case-control studies with a total of 334 participants were analyzed. Iodine-131-lipiodol treatment achieved significantly lower rates of intrahepatic recurrence (OR=0.48, 95 % confidence interval (95 % CI)=0.30-0.74; P=0.001) and early recurrence (<2 year) (OR=0.45, 95 % CI=0.23-0.89; P=0.02). Likewise, iodine-131-lipiodol treatment improved both the 5-year disease-free survival and overall survival significantly (OR=1.85, 95 % CI=1.13-3.03; P=0.01; OR=2.00, 95 % CI=0.99-4.04; P=0.05, respectively). Adjuvant intrahepatic injection of iodine-131-lipiodol resulted in a preventive effect on recurrence and improved survival after resection of HCC. Further larger, multi-centred, randomized prospective trial is warranted.

show abstract

Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma

Cited by 112 publications

References 33 publications

Effect of Adjuvant Interferon Therapy on Hepatitis B/C Virus-Related Hepatocellular Carcinoma After Curative Therapy - Meta-Analysis

Effect of Adjuvant Interferon Therapy on Hepatitis B/C Virus-Related Hepatocellular Carcinoma After Curative Therapy - Meta-Analysis

Comparison of improved prognosis between hepatitis B‐ and hepatitis C‐related hepatocellular carcinoma

Adjuvant Intrahepatic Injection Iodine-131-Lipiodol Improves Prognosis of Patients with Hepatocellular Carcinoma After Resection: a Meta-Analysis

Contact Info

Product

Resources

About